Elisabete Rios

Elisabete Rios

Auto-generated profile, based on publicly available information

Elisabete Rios

Department of Pathology, ULS São João, Porto, Portugal; Department of Oncology and Pathology, Faculty of Medicine, University of Porto, Porto, Portugal

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2026 in ESMO Open
Verified
Journal Article
Open access
OKOtilia Kimpel
Otilia Kimpel
DCD. Cosentini
D. Cosentini
ACA. Calabrese
A. Calabrese
AJA. Jouinot
A. Jouinot
BAB. Altieri
B. Altieri
MFMartin Fassnacht
Martin Fassnacht
In 2022, the World Health Organization (WHO) classified adrenal cortical carcinoma (ACC) into four subtypes: conventional, oncocytic, myxoid, and sarcomatoid. The differences in prognosis among these subtypes remain unclear. This European Network for the Study of Adrenal Tumours (ENSAT) multicentre study examines the differences not only in outcomes but also in the clinical management of patients with different ACC subtypes. Patient characteristics and survival data were retrospectively collected and analysed using Kaplan-Meier, multivariate Cox regression, and matched propensity score analyses (1 : 3 ratio) to compare recurrence-free survival (RFS) and overall survival (OS) for each subtype against conventional ACC. RFS was investigated only in patients after R0 resection, whereas OS was evaluated in the whole cohort. Matching was done for sex, age, and ENSAT tumour stage. The study included 1098 conventional, 179 oncocytic, 28 myxoid, and 10 sarcomatoid ACCs. RFS (in 653 conventional, 127 oncocytic, 15 myxoid, and 6 sarcomatoid ACCs) and OS (in all patients) were significantly longer in oncocytic ACC compared with the other groups, which was confirmed by multivariate Cox regression analyses {hazard ratio (HR) for RFS using conventional ACC as reference: oncocytic 0.47 [95% confidence interval (CI) 0.34-0.66], myxoid 0.92 (0.49-1.71), and sarcomatoid 0.83 (0.13-2.13) and for OS: oncocytic 0.37 (0.22-0.61), myxoid 1.02 (0.50-2.1), and sarcomatoid 0.82 (0.11-5.94)}. Similar results were seen after propensity score matching. RFS and OS were significantly longer in oncocytic ACC compared with the matched conventional ACC (RFS HR 0.41, 95% CI 0.29-0.55, P < 0.001; OS HR 0.35, 95% CI 0.24-0.52, P < 0.001).In metastatic oncocytic ACC, mitotane was similarly effective as in conventional tumours, but platinum-based chemotherapy seemed to result in longer progression-free survival. Stage-adjusted outcome in oncocytic ACC is better than in other subtypes.

30 March 2026 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
RLRita Lino
Rita Lino
ERElisabete Rios
Elisabete Rios
Sofia R. ValdoleirosSofia R. Valdoleiros
Sofia R. Valdoleiros